Abstract
Atherosclerosis is increasingly recognised as an inflammatory disease. The inflammatory process begins with the oxidation of low-density lipoprotein (LDL) in the artery wall. The ability of high-density lipoprotein (HDL) to inhibit the oxidation of LDL (and cell membranes) and promote macrophage cholesterol efflux through the action of several of its associated proteins, particularly paraoxonase-1 (PON1), reduces the inflammation associated with atherosclerosis. In vivo, in animal models, ablation of the PON1 gene is pro-inflammatory and pro-atherogenic, while overexpression of human PON1 is anti-inflammatory and anti-atherogenic. In subjects with diabetes mellitus, PON1 is dysfunctional due to glycation, reducing its ability to retard LDL and cell membrane oxidation and contributing to the inflammation typical of diabetes, leading to the excess atherosclerosis common in this disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ansell, B.J., Fonarow, G.C., Fogelman, A.M. (2007) The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18: 427–434.
Ansell, B.J., Navab, M., Hama, S., Kamranpour, N., Fonarow, G., Hough, G. et al. (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favourably affected by simvastatin treatment. Circulation 108: 2751–2756.
Arrol, S., Mackness, M.I., Durrington, P.N. (1996) High-density lipoprotein associated enzymes and the prevention of low-density lipoprotein oxidation. Eur J Lab Med 4: 33–38.
Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogul, J., Hsu, C., Dunlop, C., La Du, B.N (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscl Thromb Vasc Biol 10: 1617–1624.
Aviram, M., Rosenblat, M. (2004) Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37: 1304–16.
Feingold, K.R., Memon, R.A., Moser, A.H., Grunfeld, C. (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307–315.
Ferretti, G., Bacchetti, T., Busni, D., Rabini, R.A., Curatola, G. (2004) Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 89: 2957–2962.
Liu, Y., Mackness, B., Mackness, M., (2008) Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Radic Biol Med 45:743–748
Lusis, A.J. (2000) Atherosclerosis. Nature 407: 233–241.
Mackness, B., Mackness, M. (2009) HDL - Why all the fuss? Ann Clin Biochem- 46:5–7
Mackness, B., Hine, D., Liu, Y. Mastorikou, M., Mackness, M. (2004) Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. BBRC 318: 680–683.
Mackness, B., Hine, D., McElduff, P., Mackness, M. (2006) High C-reactive protein and low paraoxonase 1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 185: 396–401.
Mackness, B., Hunt, R., Durrington, P.N., Mackness, M.I. (1997) Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17: 1233–1238.
Mackness, B., Quarck, R., Verreth, W., Mackness, M., Holvoet, P. (2006a) Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 26:1545–1550.
Mackness, M.I., Arrol, S. & Durrington, P.N. (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letts 286: 152–154.
Mackness, MI., Durrington, PN., Mackness, B. (2002) The role of paraoxonase in lipid metabolism. In: Costa, LG., Furlong, CE (eds.). Paraoxonase (PON1) in health and disease. Norwell, MA: Kluwer.
Marathe, G.K., Zimmerman, G.A., McIntyre, T.M. (2003) Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 278: 3937–3947.
Marsillach, J., Mackness, B., Mackness, M., Riu, F., Beltran, R., Joven, J., Camps, J. (2008) Immunohistochemical analysis of paraoxonases- 1, 2, and 3 expression in normal mouse tissues. Free Rad Biol Med 45: 146–157.
Mastorikou, M., Mackness, B., Liu, Y., Mackness, M. (2008) Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolise membrane lipid hydroperoxides. Diabetic Med 25: 1049–1055.
Mastorikou, M., Mackness, M., Mackness, B. (2006) Defective metabolism of oxidised-phospholipid by high-density lipoprotein from people with type 2 diabetes. Diabetes 55: 3099–3103.
Miller G.J., Miller N.E. (1975) Plasma high-density lipoprotein concentration and the development of ischaemic heart disease. Lancet 1: 16–19.
Navab, M., Imes, S.S., Hama, S.Y., Hough, G.P., Ross, L.A., Bork, R.W., Valente, A.J., Berliner, J.A., Drinkwater, D.C., Laks, H. & Fogelman, A.M. (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88: 2039–2046.
Nicholls, S.J., Dusting, G.J., Cutri, B. Bao, S., Drummond, G.R., Rye K-A., Barter, P.J. (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by periarterial collar in normocholesterolemic rabbits. Circulation 111: 1543–1550.
Rodrigo, L., Mackness, B., Durrington, P.N., Hernandez, A., Mackness, M.I. (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 354: 1–7.
Ross, R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990’s. Nature 362: 801–809.
Shih, D.M., Gu, L., Xia Y-R., Navab, M., Li, W-F., Hama, S., Castellani, L.W., Furlong, C.E., Costa, L.G., Fogelman, A.M., Lusis, A.J. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284–287.
Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C. and Witztum, J.L. (1989) Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 320: 915–924.
Watson, A.D., Berliner, J.A., Hama, S.Y., La Du, B.N., Fault, K.F., Fogelman, A.M., Navab, M. (1995)Protective effect of high density lipoprotein associated paraoxonase - Inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 96: 2882–2891.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this paper
Cite this paper
Mackness, B., Mackness, M. (2010). Anti-Inflammatory Properties of Paraoxonase-1 in Atherosclerosis. In: Reddy, S. (eds) Paraoxonases in Inflammation, Infection, and Toxicology. Advances in Experimental Medicine and Biology, vol 660. Humana Press. https://doi.org/10.1007/978-1-60761-350-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-60761-350-3_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-349-7
Online ISBN: 978-1-60761-350-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)